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M A J O R A R T I C L E
Short- and Long-Term Attributable Costs
of Clostridium difficile–Associated Disease
in Nonsurgical Inpatients
Erik R. Dubberke,1 Kimberly A. Reske,1 Margaret A. Olsen,1 L. Clifford McDonald,2 and Victoria J. Fraser1
1Washington University School of Medicine, Saint Louis, Missouri; and 2Centers for Disease Control and Prevention, Atlanta, Georgia
(See the editorial commentary by Paladino and Schentag on pages 505–6)
Background. The incidence of Clostridium difficile–associated disease (CDAD) is increasing. There are few data
on the short-term and long-term attributable costs of CDAD. The objective of this study was to determine the
acute and 180-day attributable inpatient costs of CDAD.
Methods. We performed a retrospective cohort study of all patients without operating room costs who were
admitted for 48 h to Barnes-Jewish Hospital, a tertiary care hospital in St. Louis, Missouri, 1 January 2003–31
December 2003 ( ). Attributable costs of CDAD were determined by multivariable linear regression andnp 24,691
propensity-score matched-pairs analyses ( ) for the hospitalization in which CDAD occurred and per patientnp 684
over a 180-day period, including the initial hospitalization.
Results. CDAD was associated with $2454 (95% confidence interval, $2380–$2950; increase in cost, 41%)
attributable costs per CDAD episode by linear regression and with $3240 attributable costs ( ; increase inP ! .001
cost, 33%) by propensity-score matched-pairs analysis. CDAD was associated with $5042 (95% confidence interval,
$3797–$6481; increase in cost, 53%) attributable inpatient costs over 180 days by linear regression and with $7179
attributable costs for inpatient care ( ; 48% increase in costs) by propensity-score matched-pairs analysis.P ! .001
Conclusions. CDAD was associated with a significant increase in costs for inpatient care and increased costs
at 180 days after the initial hospitalization when the CDAD episode occurred.
Clostridium difficile–associated disease (CDAD) is the
most common infectious cause of hospital-associated
diarrhea [1]. A recent study using International Clas-
sification of Diseases, 9th Revision, Clinical Modification
(ICD-9), codes to measure CDAD prevalence found
that the proportion of hospital discharges that were
assigned the CDAD ICD-9 code (008.45) increased
from 0.37% in 2000 to 0.51% in 2003, for an estimated
178,000 CDAD cases in patients discharged from short-
stay hospitals in 2003 [2]. The occurrence of recent
outbreaks with unexpectedly high numbers of severe
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CDAD cases, many caused by the North American
pulsed field gel electrophoresis type 1 strain of C. dif-
ficile, suggests that the epidemiology of CDAD is chang-
ing [3–7]. Despite its importance as a hospital patho-
gen, there are few studies of the financial burden of
CDAD. No studies have evaluated costs associated with
CDAD beyond the hospitalization when CDAD oc-
curred [8–12]. The objective of the present study was
to determine the attributable total costs of treatment
of CDAD infections in nonsurgical inpatients, both for
the index hospitalization and over a 180-day period
starting with the index hospitalization.
METHODS
Study design. This study was conducted at Barnes-
Jewish Hospital (BJH), a 1250-bed tertiary care hospital
in St. Louis, Missouri. Data were collected electronically
from the hospital’s Medical Informatics and Trendstar
financial databases. The Informatics database was que-
ried to identify all patients admitted to BJH from 1
January 2003, through 31 December 2003. Data were
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Age, median years (range) 67 (18–101) 54 (13–106)
Male sex, no. (%) 214 (49) 9470 (39)
White race, no. (%) 288 (66) 13,595 (56)
Length of stay, median days (range) 10 (2–87) 4 (2–290)
Total costsa, median US$ 15,906 6821
Direct costs, median US$ 8581 3563
Charges, median US$
Total 32,597 14,068




Respiratory therapy 2843 1238
Physical therapy 647 456
NOTE. for all comparisons (by Mann-Whitney U test for continuous vari-P ! .001
ables and by x2 test for categorical variables).
a Total costs include direct, indirect, and fixed costs.
collected on demographic characteristics, hospital ward(s), in-
patient mortality, ICD-9 discharge and procedure codes, in-
patient medications ordered, vital signs, and laboratory results.
Total hospital costs (direct, indirect, and fixed) were collected
from the Trendstar financial database for each patient. Case
patients with CDAD were defined as any inpatient with a pos-
itive stool toxin assay for C. difficile (TechLab). Because the
hospital laboratory performs a test for C. difficile only on un-
formed stool samples from patients with a clinical suspicion
of CDAD, all patients with positive toxin results were consid-
ered to be case patients with CDAD. The analyses included
health care–onset and community-onset CDAD cases.
Attributable costs of CDAD were assessed both for individual
hospitalizations and per patient over a 180-day period. For the
former analysis, all nonsurgical admissions with a stay 48 h
during the study period were included. Admissions with a stay
!48 h were excluded, to limit the number of patients not at
risk or at very low risk for CDAD. Nonsurgical admissions
were defined by the absence of operating room costs. Surgical
patients were excluded, because preliminary data analysis in-
dicated that the distribution and predictors of costs were very
different in patients with operating room costs compared with
those of other hospitalized patients. For the 180-day analysis,
the index hospitalization for case patients with CDAD was the
patient’s first toxin-positive admission during the study period.
For noncases with 11 admission during the study period, 1
admission per patient during the study period was randomly
selected as the index admission. For both patients with and
without CDAD, the Informatics database was then queried to
identify all subsequent admissions to BJH within 180 days after
the index admission. Total hospital costs for each admission,
including the index hospitalization, were summed to obtain a
total for all admissions over the 180-day period. Diagnoses,
procedures, and medications from the index hospitalization
were used to predict costs over the 180-day period.
Data analysis. The first method for determining attrib-
utable cost used in this study was multivariable linear regres-
sion. Natural log–transformed total costs were used as the out-
come variable, to normalize the distribution of costs. The
primary independent variable was CDAD case status. Frequency
analyses were performed on ICD-9 code data, to identify other
variables that might be important predictors of costs. Comor-
bidities were classified by the Deyo adaptation of the Charlson
Comorbidity Index [13, 14]. A modified Acute Physiology Score
was calculated on the basis of laboratory results and vital signs
collected within 24 h after admission [15]. The Acute Physi-
ology Score was modified, because data for respiratory rate and
Glasgow Coma Score were not available electronically. In ad-
dition, albumin levels measured within 24 h after admission
were collected and categorized into normal (13.5 g/dL), low
(2.5–3.5 g/dL), and very low (!2.5 g/dL). Missing laboratory
results and vital signs were classified in the normal range. Case
patients with CDAD were considered to be exposed to a med-
ication only if the order start date was before the collection
date of the patient’s first positive stool toxin assay.
Linear regression models were built using backwards stepwise
regression, with use of for entry and for exclu-P .05 P 1 .15
sion criteria. All biologically plausible variables met entry cri-
teria. Variables that applied to !10 patients were excluded. Of
the continuous variables, only the modified Acute Physiology
Table 2. Linear regression analysis of total hospital costs per hospitalization (selected
variables).
Variable Coefficient P












Male sex 0.01 .04
White race 0.03 !.001
Modified Acute Physiology Score 0.01 !.001
Albumin level
Normal (13.5 g/dL) Reference
Low (2.5–3.5 g/dL) 0.06 !.001
Very low (!2.5 g/dL) 0.11 !.001
Received gastric acid suppressor 0.09 !.001
Received chemotherapy 0.30 !.001
Leukemia/lymphoma 0.29 !.001
Transplantation 0.49 !.001
Bacteremia, septicemia, or fungemia 0.07 !.001
Received treatment with a fluoroquinolone
0 days Reference
14–7 days 0.24 !.001
17–14 days 0.41 !.001
114 days 0.50 !.001
Received treatment with a third- or fourth-generation cephalosporin
0 days Reference
12–4 days 0.06 !.001
14–7 days 0.24 !.001
17–14 days 0.34 !.001
114 days 0.35 !.001
NOTE. Other variables included in the model were age, 31–35, 41–60, and 91 years; receiving
treatment with 10–2 days or 12–4 days of fluoroquinolone; receiving treatment with 10–2 days of third-
or fourth–generation cephalosporin; staying on the chronic ventilation floor; receiving an antidiarrheal,
laxatives, or narcotics; congestive heart failure; cerebral vascular disease; chronic obstructive pulmonary
disease; peripheral vascular disease; moderate or severe liver disease; paraplegia/hemiplegia; cancer
(excluding leukemia/lymphoma); metastatic solid tumor; obesity; endoscopy; G tube placement; insertion,
repair, or removal of a pacemaker or defibrillator; angioplasty and stent placement (coronary and non-
coronary), cardiac stress tests, pacemaker, and defibrillator checks; cardiac arrest; cardiac catheterization;
atrial fibrillation; aneurysm repair; acute renal failure; pleurisy, pneumothorax, or pulmonary collapse;
central venous catheter placement; minor surgery or procedures on colon or small intestine; anemia;
neutropenia; cystic fibrosis; deep venous thrombosis or pulmonary embolism; gunshot wound or motor
vehicle accident; cesarean section; preeclampsia or eclampsia; vaginal delivery; other obstetrical pro-
cedures; early or threatened labor; polyhydramnios, oligohydramnios, or other amniotic cavity or
membrane problems; staying on psychiatry ward; dementia; episodic mood disorders; psychiatric so-
matotherapy; convulsions; urinary tract infection or pyelonephritis; nausea and/or vomiting; adverse drug
event or overdose; cardiomyopathy; schizophrenia; obsessive-compulsive disorder; depression; receiving
amoxicillin or ampicillin, receiving clindamycin, receiving metronidazole, receiving intravenousvancomycin,
receiving macrolide, receiving first- or second-generation cephalosporin, receiving antifungal treatment,
receiving antiviral treatment; number of procedures performed; number of days in an intensive care unit;
and time to death after admission.
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mean US$ (95% CI)
Non-CDAD admissionsa 9753 5940 (5761–6125)
CDAD admissionsb 14,570 8394 (8141–9074)
Attributable costs 3240c 2454 (2380–2950)
Increase in costs, % 33 41
a Admissions for linear regression, 24,252; admissions for matched-pairs analysis, 342.
b Admissions for linear regression, 439; admissions for matched-pairs analysis, 342.
c Median difference in costs between case-control pairs.
Score met the assumptions for inclusion as a continuous var-
iable; all other variables were analyzed categorically. All levels
of categorical variables were retained in the regression models.
All independent variables were checked for colinearity. The
models were checked for functional form misspecification with
Ramsey’s regression specification error test and for heteroske-
dasticity with the Breusch-Pagan test [16]. Both linear regres-
sion models (hospitalization costs and 180-day costs) were
found to have significant heteroskedasticity ( ). A generalP ! .05
linear model (GLM) with calculation of feasible generalized
least-squares parameter estimates was used to adjust for het-
eroskedasticity. Because the GLM model used the natural log-
arithm of costs—ln(costs)—as the dependent variable, an in-
termediate regression was performed to predict costs [16].
Attributable costs of CDAD were calculated as follows. The
regression coefficient of each variable (other than CDAD) was
multiplied by the mean value for each variable or the fraction
of patients in the entire cohort who were positive for the var-
iable of interest and was added to the constant. The regression
equation was solved individually for the case patients
( ) and for the comparison group ( ) andCDADp 1 CDADp 0
was back-transformed by taking the exponent of the result. The
attributable costs of CDAD were calculated by subtracting the
difference in calculated costs between the 2 models.
The second method for determining attributable costs used
in this study was propensity-score matched-pairs analysis [17].
A logistic regression model to predict risk of CDAD was created
that contained all variables that might impact either risk of
CDAD or hospital costs, with CDAD as the outcome. Predicted
probabilities to develop CDAD from this model were used to
match case patients to control subjects by the nearest-neighbor
method [18]. One control subject was selected per case patient.
Case patients for whom a suitable control subject could not be
found were excluded. Attributable costs were calculated using
the median difference in costs between case-control patient
pairs.
Analyses were performed with SPSS, version 14.0 (SPSS),
and Stata, version 9.2 (StataCorp). The Washington University
Human Research Protection Office approved this study.
RESULTS
Characteristics of the cohort are given in table 1. The cohort
included 439 CDAD admissions and 24,252 non-CDAD ad-
missions. Case patients with CDAD were significantly older,
had a longer length of stay, and were more likely to be male
or white than were subjects without CDAD (for all, ).P ! .001
Median unadjusted total costs were higher for case patients
with CDAD than for patients without CDAD ($15,906 vs.
$6821; ). When total hospitalization costs were cate-P ! .001
gorized by selected departments, case patients with CDAD had
significantly higher costs than did noncase patients for each
cost center analyzed ( ).P ! .001
Selected variables from the final linear regression model for
CDAD costs per hospitalization in the nonsurgical cohort are
given in table 2. More than 100 variables were included in the
final model. CDAD remained an independent predictor of total
costs after adjustment for a variety of variables ( ). OtherP ! .001
variables that strongly impacted costs include chemotherapy,
insertion or repair of a pacemaker or defibrillator, coronary
angioplasty or stent placement, aneurysm repair, cystic fibrosis,
transplantation, psychiatric somatotherapy, treatment with an-
timicrobials for 11 week, having a large number of procedures
performed, staying in an intensive care unit for 1 week, and
death 2 weeks after hospital admission.
In the propensity-score matched-pairs analyses, 342 case pa-
tients were matched with 342 control patients ( ). Ap-np 684
propriate control patients could not be found for 48 patients
with CDAD. Unmatched case patients had significantly higher
modified Acute Physiology Scores than did matched case pa-
tients (median, 7.5 vs. 5.0; ), and unmatched case pa-P ! .001
tients were more likely to have leukemia or lymphoma than
were matched case patients (33% vs. 11%; ). Un-P ! .001
matched case patients had significantly higher costs than did
matched case patients, both during the index hospitalization
(median, $35,751 vs. $14,570; ) and over 180 days (me-P ! .001
dian, $47,827 vs. $27,385; ).P ! .001
In the cohort, after back-transformation, the adjusted costs
of a non-CDAD admission were $5940, and the adjusted costs
Table 4. Linear regression analysis of total hospital costs over 180 days (selected
variables).
Variable Coefficient P












Male sex 0.03 .01
White race 0.03 !.001
Modified Acute Physiology Score 0.01 !.001
Albumin level
Normal (13.5 g/dL) Reference
Low (2.5–3.5 g/dL) 0.10 !.001
Very low (!2.5 g/dL) 0.13 !.001
Received gastric acid suppressor 0.12 !.001
Received chemotherapy 0.40 !.001
Leukemia/lymphoma 0.50 !.001
Received treatment with a fluoroquinolone
0 days Reference
14–7 days 0.24 !.001
17–14 days 0.37 !.001
114 days 0.50 !.001
Received treatment with a third- or fourth-generation cephalosporin
0 days Reference
10–2 days 0.08 !.001
14–7 days 0.18 !.001
17–14 days 0.22 !.001
114 days 0.34 !.001
NOTE. Other variables included in the model were age, 41–50 or 71–95 years; receiving 10–2 or 12–
4 days of treatment with fluoroquinolone; receiving 12–4 days of treatment with third- or fourth–generation
cephalosporin; staying on the chronic ventilation floor; receiving antidiarrheals; receiving laxatives; re-
ceiving narcotics; congestive heart failure; cerebrovascular disease; moderate or severe liver disease;
diabetes with chronic complications; cancer (excluding leukemia/lymphoma); metastatic solid tumor; G
tube placement; insertion, repair, or removal of a pacemaker or defibrillator; angioplasty and stent place-
ment (coronary and noncoronary); cardiac stress tests, pacemaker, and defibrillator checks; cardiac arrest;
atrial fibrillation; aneurysm repair; acute renal failure; pleurisy, pneumothorax, pulmonary collapse; central
venous catheter placement; minor surgery or procedures on colon or small intestine; anemia; neutropenia;
cystic fibrosis; deep venous thrombosis or pulmonary embolism; cesarean section; preeclampsia or
eclampsia; vaginal delivery; early or threatened labor; polyhydramnios, oligohydramnios, or other amniotic
cavity or membrane problems; staying on psychiatry ward; dementia; episodic mood disorders;psychiatric
somatotherapy; convulsions; obesity; incision of pleura/thoracentesis; urinary tract infection or pyelone-
phritis; receiving antifungal; receiving antiviral; number of procedures performed; number of days in an
intensive care unit; time to death after index admission; dialysis; hypertension; diabetes; adverse drug
event or drug overdose; schizophrenia; depression; sickle cell anemia; number of admissions in previous
60 days; received treatment with amoxicillin or ampicillin; received treatment with metronidazole; received
treatment with intravenous vancomycin; received treatment with macrolide; received first- or second-
generation cephalosporin.
502 • CID 2008:46 (15 February) • Dubberke et al.






mean US$ (95% CI)
Non-CDAD admissiona 14,970 9518 (9107–9947)
CDAD admissionb 27,385 14,560 (12,905–16,428)
Difference (attributable costs) 7179c 5042 (3797–6481)
Increase in costs, % 48 53
a Admissions for linear regression, 17,663; admissions for matched-pairs analysis, 342.
b Admissions for linear regression, 390; admissions for matched-pairs analysis, 342.
c Median difference in costs between case-control pairs.
of a CDAD admission were $8394, for attributable costs of
$2454 (95% CI, $2380–$2950) (table 3). In the propensity-
score matched-pairs analysis, the median costs of a control
admission were $9753, and the median costs of a case admission
were $14,570 ( , by Wilcoxon signed rank test); the me-P ! .001
dian attributable costs of CDAD calculated from the matched
pairs were $3240. When multiplied by the 439 CDAD admis-
sions, the resulting median attributable costs of CDAD in non-
surgical inpatients per admission over a 1-year period at BJH
were estimated to be between $1,077,306 (regression model
estimate) and $1,422,360 (matched-pairs estimate).
The analysis of attributable inpatient costs over 180 days
included 390 patients with CDAD and 17,663 patients without
CDAD. Selected variables from the final linear regression model
for CDAD costs over the 180-day follow-up period are given
in table 4. CDAD remained an independent predictor of total
inpatient costs over 180 days, after adjustment for many var-
iables ( ). Other important predictors of increased costsP ! .001
over the follow-up period included chemotherapy, leukemia/
lymphoma, insertion or repair of a pacemaker or defibrillator,
coronary or noncoronary angioplasty or stent placement, an-
eurysm repair, minor abdominal surgery or procedures, cystic
fibrosis, psychiatric somatotherapy, treatment with antimicro-
bials for 11 week, having a large number of procedures per-
formed, staying in an intensive care unit for6 days, and death
within 1 week after hospital admission.
After back-transformation, the adjusted sum cost for ad-
missions for patients without CDAD over the 180-day period
was $9518, and the adjusted sum for patients with CDAD was
$14,560, for attributable costs of $5042 (95% CI, $3797–$6481)
(table 5). In the propensity-score analysis, the median sum cost
of inpatient admissions over the 180-day period for CDAD
cases was $27,385. The median sum cost of control admissions
was $14,970 ( , by Wilcoxon signed rank test). ThePp .001
median attributable costs of CDAD calculated from the
matched-pairs analysis were $7179. When multiplied by the
390 CDAD admissions, the resulting median attributable costs
of CDAD over 180 days at BJH were estimated to be between
$1,966,380 (regression model estimate) and $2,799,810
(matched-pairs estimate).
DISCUSSION
In this study, to our knowledge the largest to date evaluating
the attributable costs of CDAD, CDAD was associated with
increased costs during the CDAD hospitalization and increased
inpatient costs extending 180 days from the initial CDAD ad-
mission. These estimates were established using 2 different
methods for determining attributable costs: multivariable GLM
regression and propensity-score matched pairs. The attributable
costs of CDAD ranged from $2454 (41% increase in costs over
non-CDAD admissions) by regression analyses to $3240 (33%
increase in costs) by propensity-score matched-pairs analyses.
The increase in 180-day attributable costs of CDAD ranged
from $5042 (53% increase in costs) by regression analyses to
$7179 (48% increase in costs) by propensity-score matched-
pairs analyses.
A key strength of this analysis is the use of 2 different meth-
ods to estimate costs. The “true” attributable costs of CDAD
are unknown, but the different models used here provide a
realistic range in which the true attributable costs may fall.
Both analysis methods have advantages and disadvantages. A
weakness of the propensity-scores method is the loss of some
cases that could not be matched to controls; the GLM-regres-
sion method allows analysis of the entire cohort. The GLM-
regression model may have unmeasured confounders, but in
the propensity-scores method, case and control patients are
matched using data from a large number of variables, to min-
imize potential confounding.
The attributable costs estimates generated by both methods
are remarkably consistent. A closer look at the findings of this
study reveals how the results are complementary. Patients who
develop CDAD tend to be older and more severely ill than
patients who do not develop CDAD. The GLM-regression
method uses all of the cohort data, thereby including a large
number of patients at low risk for CDAD. Propensity-score
matching identifies control patients who are as similar to the
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case patients as possible and minimizes the number of control
patients who are not severely ill. The estimated per hospitali-
zation cost for a non-CDAD admission by GLM is $5940, with
attributable CDAD costs of $2454, compared with $9753 for
the matched pairs, with attributable CDAD costs of $3240 (table
3). Although the absolute attributable CDAD cost by GLM is
lower, the relative increase in costs due to CDAD is higher
(41% vs. 33%). CDAD may cost more for patients who are
sicker, but the relative increase in costs may not be as great
compared with that for less sick patients who develop CDAD.
The similarities in relative increase in costs further highlight
the consistency of these estimates. The relative increases in costs
in the 180-day analyses (by regression, 53%; by propensity-
score matched pairs, 48%) differ by only 5%.
Both analysis methods are conservative and may underes-
timate the true attributable cost of CDAD. The large number
of variables included in the GLM regression may have biased
costs toward a lower value by attributing some of the costs
associated with CDAD to other variables that occurred after
CDAD diagnosis (for example, admission to an intensive care
unit after CDAD diagnosis). In the propensity-score matched-
pairs analysis, 48 CDAD cases were excluded. These case pa-
tients were more severely ill than were the matched case patients
and had higher median costs for both the index hospitalization
and over the 180 days after the index hospitalization.
Data on the cost of CDAD are surprisingly rare, and data
on attributable costs are even rarer. Wilcox et al. [11] estimated
the costs of a CDAD infection to be £4107. Miller et al. [10]
estimated the costs of hospital readmission due to CDAD in
Canada to be $128,200 (in Canadian dollars) per hospital per
year. In 1 of only 3 published CDAD cost analyses performed
in the United States, Kofsky et al. [8] estimated overall charges
of $334,000 for treatment of 155 patients with CDAD, for an
individual cost of ∼$2000 per patient. The greatest limitation
of these previous studies is that none of them calculated the
attributable costs of CDAD; instead, costs were estimated by
either summing various patient charges or by extrapolating
general costs (e.g., cost to be hospitalized 1 day) over averages
for a known number of patients with CDAD. Similarly, in the
recent study by O’Brien et al. [12], the mean excess costs of
CDAD were estimated to be $13,675 per case. This estimate is
much higher than those of previously published estimates, but
the estimate was derived from differences in length of stay
between CDAD and non-CDAD patients (stratified by severity
of illness) and does not constitute a true attributable costs.
Notably, the median excess costs of $5442 reported by O’Brien
et al. [12] for secondary case patients with CDAD was much
closer to those of other published estimates.
Kyne et al. [9] performed the only analysis of CDAD-at-
tributable costs published to date. The researchers used a cohort
study design and linear regression to estimate attributable costs
and found the attributable costs of CDAD to be $3669 (95%
CI, $1126–$7024) per episode. The analysis presented here has
several advantages over the analysis performed by Kyne et al.
[9]. The first is sample size; the study population at BJH in-
cluded 439 CDAD cases, compared with 47 in the study of
Kyne et al. [9]. Second, the analysis presented here may be
more generalizable than is the analysis performed by Kyne et
al. [9], which was limited to 3 medical wards. Finally, Kyne et
al. [9] estimated total hospital costs by adjusting hospital
charges with the overall Medicare cost-to-charge ratio for their
institution. In the present analysis, the cost-to-charge ratio was
individualized by department, thereby providing a more ac-
curate estimate of the actual costs of each inpatient admission.
The analysis of CDAD costs over 180 days performed in this
study indicated that CDAD continues to be a significant pre-
dictor of inpatient costs extending beyond the costs of a pa-
tient’s initial CDAD hospitalization. This finding has not been
reported previously. The attributable costs of the index ad-
mission plus readmissions within 180 days are likely to be in
the range between our linear regression estimate ($5042) and
our propensity-score estimate ($7179). However, these figures
underestimate the overall long-term attributable costs of
CDAD, because we did not have data on outpatient costs (e.g.,
outpatient clinic visits, outpatient medication use, or rehabil-
itation), long-term care facility costs, cost of admissions to
another acute care facility, or costs from loss of work due to
CDAD. The lack of these data is a limitation of this study.
Furthermore, because this study included only inpatients with-
out operating room costs, patients with CDAD who received
colectomies were excluded. A future study that incorporates all
health care costs and includes information about surgical pa-
tients would provide a more accurate estimate of the true total
attributable costs of CDAD.
CDAD significantly increases hospital costs, even when the
conservative estimates presented here are applied. On the basis
of these results, in 2003, CDAD infections cost 1$1 million at
BJH alone. McDonald et al. [2] found the CDAD ICD-9 code
cited in 178,000 discharges from short-stay hospitals in the
United States in 2003. With use of this estimate, the national
attributable costs of CDAD per CDAD hospitalization in 2003
were $436–$580 million. The long-term costs of CDAD may
be even greater. In 2003, patients who developed CDAD in-
curred 180-day costs of $1.9–$2.8 million at BJH. When mul-
tiplied by the estimate of McDonald et al. [2] of 178,000 US
CDAD cases, the estimated attributable 180-day costs of CDAD
cases in the United States in 2003 were ∼$897 million—$1.3
billion.
Anecdotal reports of outbreaks with the North American
pulse-field type 1 strain of C. difficile since 2003 indicate that
CDAD rates are increasing. More-recent estimates suggest that
as many as 250,000 hospitalizations in the United States during
504 • CID 2008:46 (15 February) • Dubberke et al.
2005 were complicated by CDAD (Centers for Disease Control
and Prevention, unpublished data). In addition, CDAD severity
may also be increasing. Thus, the financial burden of CDAD
is likely increasing as well. The high attributable costs of CDAD
may help justify allocation of resources to CDAD prevention
in hospitals and emphasize the need for additional scientific
research on CDAD [19, 20]. Future studies of CDAD inter-
ventions can assess cost-effectiveness of those interventions
with use of the estimates provided here.
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